• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Ocular Therapeutix (OCUL)'s AXPAXLI NDA Timeline and FDA Feedback Means For Shareholders

    Simply Wall St·09/05/2026 14:23:58
    Listen to the news
    • Ocular Therapeutix recently presented new data on its lead retinal candidate AXPAXLI at the 19th Asia-Pacific Vitreo-retina Society Congress, while confirming it remains on schedule to submit a new drug application for wet age-related macular degeneration in the fourth quarter of 2026 under the FDA’s 505(b)(2) pathway.
    • The company’s disclosure that SOL-1 trial data and additional safety evidence are expected to be sufficient for filing, alongside higher spending ahead of a potential launch and cash projected to last into 2028 despite further dilution, underscores how close AXPAXLI is moving toward a potential commercial inflection point.
    • Next, we’ll examine how this reaffirmed AXPAXLI NDA timeline and supportive FDA feedback may influence Ocular Therapeutix’s broader investment narrative.

    This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

    Ocular Therapeutix Investment Narrative Recap

    To own Ocular Therapeutix, you have to believe AXPAXLI can successfully clear the FDA path for wet AMD and support a viable commercial franchise despite ongoing losses. The latest APVRS update largely reinforces that view, keeping the fourth quarter 2026 NDA as the key near term catalyst, while the biggest immediate risk remains any clinical or regulatory hiccup around SOL-1 or supporting safety data that could disrupt that filing plan.

    In this context, the April 2026 disclosure of positive Week 52 SOL-1 data and FDA support for an NDA based on that single pivotal trial looks even more important. Together with the recent confirmation of cash runway into 2028, it frames a period where spending and dilution are rising ahead of AXPAXLI’s potential launch, but the core value driver is still whether that NDA is accepted and reviewed as planned.

    Yet, while the NDA timeline appears intact, investors should also be aware that...

    Read the full narrative on Ocular Therapeutix (it's free!)

    Ocular Therapeutix's narrative projects $460.1 million revenue and $100.9 million earnings by 2029. This requires 106.8% yearly revenue growth and a $402.3 million earnings increase from -$301.4 million today.

    Uncover how Ocular Therapeutix's forecasts yield a $27.09 fair value, a 155% upside to its current price.

    Exploring Other Perspectives

    OCUL 1-Year Stock Price Chart
    OCUL 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming revenue could climb about 125% a year and earnings reach roughly US$116.8 million by 2029, so as this FDA aligned wet AMD story evolves, you may find that your own view on dilution risk and long term upside ends up quite different from theirs.

    Explore 5 other fair value estimates on Ocular Therapeutix - why the stock might be worth over 10x more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Contemplating Other Strategies?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.